History
Innovative Medicines based on
ImmunoModulatory Biologics
-
About us
-
History
Global biotechnology company
that benefits the world
2025
- 01
- Joint research on 'autoimmune' antibodies with Y-Biologics
2024
- 12
- IMB-101, Selection of the top 6 excellent projects for KDDF 2024
- 11
- Awarded the Minister of Trade, Industry and Energy Prize
- 11
- Awarded the Minister of Health and Welfare Prize
- 11
- Johnson & Johnson JLABS Korea Final Selection
- 11
- Awarded the 105th IR52 Jang Yeong-sil Prize
- 08
- IMBiologics Corp. announced a License Agreement with Huadong Medicine
- 07
- IMB-402 project funded by KEIT for Materials, Parts, and Equipment
- 06
- IMBiologics Corp. announced a License Agreement with Navigator Medicines
- 04
- IMB-201/IMB-401: poster presentation at American Cancer Society (AACR)
- 02
- Signing a joint research agreement with Dong-A ST using ePENDY platform technology
- 01
- Patent registration of ePENDY platform technology in Korea
2023
- 12
- IMB-101, Selection of the top 10 excellent projects for KDDF 2023
- 11
- IMB-101, American College of Rheumatology (ACR) 2023 conference poster
- 10
- MOU with China Canton Biologics: Strategic collaboration agreement based on ePENDY platform technology
- 07
- IMB-101, Antibody Society Korea (ASK) 2023 conference presentation
- 07
- IMB-101 : US FDA IND approval
- 07
- Completion of 20 Bil. KRW Series B Funding
- 06
- IMB-101 : US FDA IND submission
- 04
- ePENDY Platform : poster presentation at American Cancer Society (AACR)
2022
- 12
- IMB-101 : Nature biopharma dealmakers printed/online
- 11
- MOU with Dong-A ST: research based on ePENDY platform technology
- 07
- ePENDY Platform, Antibody Society Korea (ASK) 2022 conference presentation
- 03
- IMB-101 project funded by KDDF(Korea Drug Development Fund)
- 03
- The 2nd annual shareholder meeting
2021
- 08
- Completion of 13 Bil. KRW Series A Funding by KB, Atinum, Partners, IMM and Timewise investment firms
- 04
- Completion of the trademark application
- 03
- The 1st annual shareholder meeting
- 03
- Approval of the LMO facility
- 02
- Certification of the venture company
- 01
- Completion of 4 Bil. KRW Seed Funding led by KB investment and Atinum investment
2020
- 12
- Certification of the company-affiliated research institute
- 11
- Relocation of the HQ and the research institute to Gwanggyo Central Biz Tower
- 11
- Worldwide exclusive in-licensing agreement for OXTIMA(IMB-101) with HK inno.N
- 10
- Patent application for the IMB platform technology
- 09
- Temporary research institute established at Gyeonggi Bio Center
- 08
- Establishment of IMBiologics Inc.
- President(CEO) : Gyongsik Ha
- 260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea